Suven Pharmaceuticals Ltd. (IN:COHANCE)

:COHANCE

COHANCE

Suven Pharmaceuticals Ltd.

RESEARCH TOOLSreports

Want to see IN:COHANCE full AI Analyst Report?

Suven Pharmaceuticals Ltd. (COHANCE) Price & Analysis

2 Followers

COHANCE Stock Chart & Stats

₹891.10

₹6.60(0.60%)

At close: Jan 08 4:00 PM EST

₹891.10

₹6.60(0.60%)

Day’s Range― - ―

52-Week Range₹267.85 - ₹1,179.95

Previous CloseN/A

VolumeN/A

Average Volume (3M)116.47K

Market Cap

₹160.83B

Enterprise Value₹164.05B

Total Cash (Recent Filing)₹4.03B

Total Debt (Recent Filing)₹4.51B

Price to Earnings (P/E)64.3

Beta1.04

Next Earnings

Aug 07, 2026

EPS Estimate

0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)9.70

Shares Outstanding382,567,140

10 Day Avg. Volume24,499

30 Day Avg. Volume116,469

Financial Highlights & Ratios

PEG Ratio-1.16

Price to Book (P/B)2.95

Price to Sales (P/S)5.08

P/FCF Ratio85.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹300.00

Price Target Upside-66.33% Downside

Rating ConsensusModerate Sell

Number of Analyst Covering1

EPS Forecast (FY)7.16

Revenue Forecast (FY)₹25.24B

Bulls Say, Bears Say

Bulls Say

Sustained Revenue GrowthSustained double-digit top-line expansion supports CDMO scale economics and higher capacity utilization. Over 2–6 months, revenue momentum helps secure multi-phase contracts, improves bargaining power with clients, and increases the probability of converting development projects into recurring commercial supplies.

Conservative Balance SheetVery low leverage gives financial flexibility for capex, capacity expansion and working-capital swings inherent to CDMO cycles. It reduces refinancing risk and supports long-term client commitments, enabling the company to invest in compliance and complex-chemistry capabilities without immediate liquidity pressure.

Integrated CDMO Business ModelAn end-to-end CDMO model creates durable client relationships and multi-stage revenue streams (development fees then commercial supply). Handling complex chemistry and controlled substances raises technical barriers and switching costs, supporting recurring revenue and higher client retention over the medium term.

Bears Say

Margin CompressionA structural step-down in margins materially reduces earnings quality and internal funding capacity. Lower gross and net margins weaken the firm's ability to self-fund reinvestment and absorb pricing pressure, making profitability more sensitive to input costs and contract mix over the coming quarters.

Weaker Free Cash Flow ConversionDeclining FCF conversion signals more working-capital absorption or higher reinvestment, limiting cash available for debt paydown or capex. Persistently weak cash conversion can force external financing or slow strategic investments, constraining growth and increasing operational leverage risk.

Rising Absolute Debt TrendAlthough leverage is low today, the recent rise in absolute debt introduces risk if margins remain compressed. Continued debt accumulation could reduce flexibility, raise interest burden, and limit the firm's ability to absorb future project delays or client payment lags over the medium term.

Suven Pharmaceuticals Ltd. News

Cohance Lifesciences Says Volume Surge in Shares Is Market-Driven

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has shared an update. Cohance Lifesciences has responded to a query from...

1M ago

Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary and Compliance Officer

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an announcement. Cohance Lifesciences has appointed Sisir K. Mishra as...

2M ago

Cohance Lifesciences Grants 198,711 Stock Options Under ESOP 2023

An announcement from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) is now available. Cohance Lifesciences has approved the grant...

2M ago

Cohance Lifesciences to Engage Investors at IIFL and Kotak Conferences in February 2026

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) just unveiled an announcement. Cohance Lifesciences Limited has announced that its management...

3M ago

COHANCE FAQ

What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?

Suven Pharmaceuticals Ltd. lowest stock price was ₹267.85 and its highest was ₹1179.95 in the past 12 months.

What is Suven Pharmaceuticals Ltd.’s market cap?

Suven Pharmaceuticals Ltd.’s market cap is ₹160.83B.

When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?

Suven Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 77 days.

How were Suven Pharmaceuticals Ltd.’s earnings last quarter?

Suven Pharmaceuticals Ltd. released its earnings results on May 12, 2026. The company reported ₹0.95 earnings per share for the quarter, missing the consensus estimate of ₹1.14 by -₹0.19.

Is Suven Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Pharmaceuticals Ltd. pay dividends?

Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of N/A. See more information on Suven Pharmaceuticals Ltd. dividends here

What is Suven Pharmaceuticals Ltd.’s EPS estimate?

Suven Pharmaceuticals Ltd.’s EPS estimate is 0.82.

How many shares outstanding does Suven Pharmaceuticals Ltd. have?

Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding.

What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?

Suven Pharmaceuticals Ltd. reported an EPS of ₹0.95 in its last earnings report, missing expectations of ₹1.14. Following the earnings report the stock price went up 1.483%.

Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:COHANCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Pharmaceuticals Ltd.

Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical company specializing in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company was formerly known as Suven Pharmaceuticals Limited and underwent a rebranding following its merger with Cohance Lifesciences, effective May 1, 2025.

Suven Pharmaceuticals Ltd. (COHANCE) Earnings & Revenues

Historic Earnings Reports

COHANCE Stock 12 Month Forecast

Average Price Target

₹300.00

▼(-66.33% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"299":"₹299","508":"₹508","717":"₹717","926":"₹926","1135":"₹1,135"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹300.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[299,508,717,926,1135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,482.95,468.87692307692305,454.80384615384617,440.7307692307692,426.6576923076923,412.5846153846154,398.51153846153846,384.4384615384615,370.36538461538464,356.2923076923077,342.21923076923076,328.1461538461539,314.07307692307694,{"y":300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,482.95,468.87692307692305,454.80384615384617,440.7307692307692,426.6576923076923,412.5846153846154,398.51153846153846,384.4384615384615,370.36538461538464,356.2923076923077,342.21923076923076,328.1461538461539,314.07307692307694,{"y":300,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,482.95,468.87692307692305,454.80384615384617,440.7307692307692,426.6576923076923,412.5846153846154,398.51153846153846,384.4384615384615,370.36538461538464,356.2923076923077,342.21923076923076,328.1461538461539,314.07307692307694,{"y":300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1134.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1023.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":960.35,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":980.4,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":902.15,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":870.1,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":753.2,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":553.25,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":523.5,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":371,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":303.7,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":311.55,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":482.95,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >